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Abstract: BACKGROUND Identifying molecular differences between primary and metastatic colorectal
cancers-now possible with the aid of omics technologies-can improve our understanding of the biological
mechanisms of cancer progression and facilitate the discovery of novel treatments for late-stage cancer.
We compared the DNA methylomes of primary colorectal cancers (CRCs) and CRC metastases to the
liver. Laser microdissection was used to obtain epithelial tissue (10 to 25 × 106 ฀m2) from sections of
fresh-frozen samples of primary CRCs (n = 6), CRC liver metastases (n = 12), and normal colon mucosa
(n = 3). DNA extracted from tissues was enriched for methylated sequences with a methylCpG binding
domain (MBD) polypeptide-based protocol and subjected to deep sequencing. The performance of this
protocol was compared with that of targeted enrichment for bisulfite sequencing used in a previous study
of ours. RESULTS MBD enrichment captured a total of 322,551 genomic regions (249.5 Mb or 7.8%
of the human genome), which included over seven million CpG sites. A few of these regions were dif-
ferentially methylated at an expected false discovery rate (FDR) of 5% in neoplastic tissues (primaries:
0.67%, i.e., 2155 regions containing 279,441 CpG sites; liver metastases: 1%, i.e., 3223 regions containing
312,723 CpG sites) as compared with normal mucosa samples. Most of the differentially methylated
regions (DMRs; 94% in primaries; 70% in metastases) were hypermethylated, and almost 80% of these
(1882 of 2396) were present in both lesion types. At 5% FDR, no DMRs were detected in liver metastases
vs. primary CRC. However, short regions of low-magnitude hypomethylation were frequent in metas-
tases but rare in primaries. Hypermethylated DMRs were far more abundant in sequences classified as
intragenic, gene-regulatory, or CpG shelves-shores-island segments, whereas hypomethylated DMRs were
equally represented in extragenic (mainly, open-sea) and intragenic (mainly, gene bodies) sequences of
the genome. Compared with targeted enrichment, MBD capture provided a better picture of the exten-
sion of CRC-associated DNA hypermethylation but was less powerful for identifying hypomethylation.
CONCLUSIONS Our findings demonstrate that the hypermethylation phenotype in CRC liver metastases
remains similar to that of the primary tumor, whereas CRC-associated DNA hypomethylation probably
undergoes further progression after the cancer cells have migrated to the liver.
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Abstract
Background: Identifying molecular differences between primary and metastatic colorectal cancers—now possible with
the aid of omics technologies—can improve our understanding of the biological mechanisms of cancer progression and
facilitate the discovery of novel treatments for late-stage cancer. We compared the DNA methylomes of primary
colorectal cancers (CRCs) and CRC metastases to the liver. Laser microdissection was used to obtain epithelial tissue (10 to
25 × 106 μm2) from sections of fresh-frozen samples of primary CRCs (n = 6), CRC liver metastases (n = 12), and normal
colon mucosa (n = 3). DNA extracted from tissues was enriched for methylated sequences with a methylCpG binding
domain (MBD) polypeptide-based protocol and subjected to deep sequencing. The performance of this protocol was
compared with that of targeted enrichment for bisulfite sequencing used in a previous study of ours.
Results: MBD enrichment captured a total of 322,551 genomic regions (249.5Mb or ~ 7.8% of the human genome), which
included over seven million CpG sites. A few of these regions were differentially methylated at an expected false discovery
rate (FDR) of 5% in neoplastic tissues (primaries: 0.67%, i.e., 2155 regions containing 279,441 CpG sites; liver metastases: 1%,
i.e., 3223 regions containing 312,723 CpG sites) as compared with normal mucosa samples. Most of the differentially
methylated regions (DMRs; 94% in primaries; 70% in metastases) were hypermethylated, and almost 80% of these (1882 of
2396) were present in both lesion types. At 5% FDR, no DMRs were detected in liver metastases vs. primary CRC. However,
short regions of low-magnitude hypomethylation were frequent in metastases but rare in primaries. Hypermethylated DMRs
were far more abundant in sequences classified as intragenic, gene-regulatory, or CpG shelves-shores-island segments,
whereas hypomethylated DMRs were equally represented in extragenic (mainly, open-sea) and intragenic (mainly, gene
bodies) sequences of the genome. Compared with targeted enrichment, MBD capture provided a better picture of the
extension of CRC-associated DNA hypermethylation but was less powerful for identifying hypomethylation.
Conclusions: Our findings demonstrate that the hypermethylation phenotype in CRC liver metastases remains similar to
that of the primary tumor, whereas CRC-associated DNA hypomethylation probably undergoes further progression after the
cancer cells have migrated to the liver.
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binding domain, MBD capture, Differentially methylated regions
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Background
Among secondary tumors of the liver, metastases from
colorectal adenocarcinomas are the easiest to identify
histopathologically. In most cases, they exhibit glands
strongly resembling those of the primary colorectal can-
cers (CRCs), their lumens lined by tall columnar cells and
filled with necrotic debris (“dirty necrosis”) [1]. The histo-
pathological grade and differentiation capacity of a pri-
mary colorectal cancers can be even recapitulated in
xenografted tumor organoids [2]. Given the strikingly dif-
ferent environments in which the primary and metastatic
(or xenografted) tumor cells are forced to grow, this
phenotypic robustness is remarkable. It might reflect the
existence of a genetic–epigenetic program that remains
more or less unchanged, even when the CRC cells migrate
to the liver and establish a new tumor there. This hypoth-
esis is consistent with reports of high genomic concord-
ance between some primary CRCs and their metastases
[3, 4] and with claims that the DNA-methylation-based
epigenetic profile of liver metastases of unknown origin
can reliably reveal the lesions’ primary cancer source [5].
However, the genetic and epigenetic profiles of the CRC
liver metastases will never be 100% identical to those of
the primary tumor growing in the gut. Among other
things, some anticancer drugs cause genetic and/or epi-
genetic changes that favor the selection and emergence of
drug-resistant cellular clones [6]. Some degree of diver-
gence from the primary tumor is thus inevitable, and its
magnitude is probably characterized by substantial inter-
tumor and inter-tumor-type variation [7, 8]. Investigation
of this divergence requires powerful omics tools capable
of exploring most if not all of the human genome.
Genome-wide analysis of DNA methylation, for example,
can be particularly informative in this setting. During em-
bryogenesis, the DNA methylome undergoes profound re-
modeling, with the removal and addition of methyl groups
at cytosine bases, primarily those making up CpG dinucleo-
tides. These changes are associated with markedly modified
gene-expression (although the mechanisms underlying this
association are still incompletely understood) [9–13], and
play pivotal roles in the processes of cellular differentiation
and organ specification [14, 15]. Once the large intestine
methylome is established, however, it is chemically stable
and faithfully maintained by mitotic inheritance for the life
of the individual.
A major exception to this rule occurs with the onset
of neoplasia in the gut. During colorectal tumorigenesis
(as well as that occurring in other organs), many nor-
mally unmethylated CpG islands located in gene pro-
moters become heavily methylated. For a few of these
promoters, the hypermethylation has been strongly
linked to gene silencing with potentially crucial roles in
tumorigenesis. Paradigmatic is the epigenetic inactiva-
tion of the DNA mismatch repair gene MLH1, which
leads to the emergence of post-replicative DNA muta-
tions and microsatellite instability (MSI) [16]. The
hypermutator phenotype of these cancers has distinctive
effects on their prognosis and their sensitivity to chemo-
therapy [17–19]. They account for about 15% of all
CRCs, and are presently classified as consensus molecu-
lar subtype 1 in the gene-expression-based CRC classifi-
cation [20] and as MSI/CIMP-H (CpG island methylator
phenotype-high) in the TCGA classification of gastro-
intestinal cancers [21].
We recently investigated the DNA methylomes of
precancerous and cancerous colorectal lesions [13]. In
addition to our extensive characterization of the hyper-
methylation phenotype of gene regulatory genomic re-
gions in both types of tumor, we also confirmed the
presence in these lesions of another classical tumor-
associated change in the methylome: widespread hypo-
methylation. These findings were obtained with bisul-
fite sequencing of DNA subjected to targeted
enrichment for regions containing CpG islands since
whole-genome sequencing is associated with well-
known constraints in terms of costs, data storage, and
analysis. In the present study, we used methyl-CpG-
binding domain (MBD) sequencing to explore the
methylomes of normal and neoplastic colon tissues,
with the aim of discovering whether the process of
colorectal tumor-associated epigenetic remodeling con-
tinues to evolve in CRC cells that have migrated to and
established metastases in the liver. We also compared
the performances of the MBD- and targeted-




Tissues were prospectively collected at the University
Hospital of Zurich (Switzerland) with institutional re-
search ethics committee approval. Donors provided writ-
ten consent to tissue collection, testing, and data
publication. Samples were numerically coded to protect
donors’ rights to confidentiality.
Immediately after resection, samples of normal colon
mucosa, primary CRCs, and CRC liver metastases were
frozen in liquid nitrogen and stored at − 80 °C. They in-
cluded six primary tumors, three of which were accom-
panied by patient-matched samples of normal mucosa
from the same gut segment (> 2 cm from the tumor), and
twelve liver metastases (none of which were from the pri-
mary CRC donors) (Table 1). Nine patients were diag-
nosed with a single metastasis. For the three who
developed multiple metastases, the largest lesion was in-
cluded in the study. All of the primary and secondary le-
sions were microsatellite-stable and CpG island
methylator phenotype-negative.
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Laser tissue microdissection
Laser tissue microdissection was done with a CellCut system
(Molecular Machines & Industries, Glattbrugg, Switzerland).
Briefly, 10 μm-thick sections were cut with a Hyrax C60
cryostat (Zeiss, Feldbach, Switzerland) from frozen tissues
embedded in Tissue-Tek O.C.T. (i.e., optimum cutting
temperature formulation; Sakura, Alphen aan den Rijn, The
Netherlands). The sections were placed on membrane slides
(Molecular Machines & Industries), fixed in propanol for 45
s, and covered with one drop of Mayer’s hematoxylin
(MHS128, Sigma-Aldrich, Buchs, Switzerland) for 45 s. After
vigorous washing, the sections were sequentially immersed
in 0.1% ammonia (10 s), propanol (45 s), and xylene (45 s)
and dried for 5min. Stained tissues were then subjected to
laser microdissection using special tubes with caps to which
the dissected sections adhered (Molecular Machines & In-
dustries, Glattbrugg, Switzerland). Epithelial cells from nor-
mal or neoplastic crypts were selectively collected on the
cap, with care taken to minimize stromal-cell contamination.
Between 10 and 25 × 106 μm2 of dissected epithelium (= ≈
100,000 to 250,000 epithelial cells) was collected from each
sample. Immediately after dissection, DNA was extracted
with the QIAmp DNA Micro kit (Qiagen, Hombrechtikon,
Switzerland) and quantified with a Qubit fluorometer and
dsDNA HS Assay kit (Thermo Fisher Scientific, Reinach,
Switzerland) (total yield: 100–500 ng DNA).
MBD-peptide-based capture of DNA for deep sequencing
Methylated DNA for sequencing was isolated using an
MBD-capture protocol [22]. Reaction volumes were
scaled down to successfully process the small volumes of
genomic DNA obtained with laser tissue microdissec-
tion. Briefly, 100 ng of input DNA was fragmented to an
average length of 200 bp in a Covaris (Brighton, UK) S2
ultrasonicator. Recombinant MBD2 protein-mediated
enrichment (MBDE) for methylated DNA was carried
out with the MethylMiner kit (ThermoFisher, Waltham,
MA, USA) using a single elution step with 2000mM
NaCl elution buffer. Multiplex Illumina libraries were
prepared with the NEBNext Ultra DNA Library Prep Kit
(New England Biolabs, Ipswich, MA, USA), and their
sizes and concentrations were evaluated with the Agilent
(Santa Clara, CA, USA) 2200 TapeStation system.
Libraries were sequenced on an Illumina 2500 system
(Illumina, San Diego, CA, USA) (on average 50-bp
single-end reads, 40 million reads per sample).
Table 1 Characteristics of tissues included in the study
Patient number Tissue Site Lesion size (mm) Stage and grade of primary cancer a
C1c primary CRC R 30 × 25 T4aN2bR0cM1 / G2
C1n normal mucosa R
C2c primary CRC S 27 × 10 T3N0M0R0 / G3
C2n normal mucosa S
C3c primary CRC R 25 × 25 T2N1bM0 / G2
C3n normal mucosa R
C4 primary CRC T 18 × 15 T4aN0M0R0 / G2
C5 primary CRC S 50 × 20 T3N2acM1 / G2
C6 primary CRC A 30 × 25 T4aN2bcM1 / G3
M1 CRC metastasis liver 13 × 7 pT3pN2M0 / G3
M2 CRC metastasis liver 25 × 13 pT4pN0M0 / G3
M3 CRC metastasis liver 10 × 6 pT3pN0cM1 / G3
M4 CRC metastasis liver 20 × 7 pT1pN1M0 / G2
M5 CRC metastasis liver 15 × 10 pT4pN1M1 / G2
M6 CRC metastasis liver 10 × 5 pT3N0M0 / G2
M7 CRC metastasis liver 15 × 15 pT1pN1M0 / G2
M8 b CRC metastasis liver 10 × 8 pT3N1M0 / G2
M9 b CRC metastasis liver 20 × 20 pT3N0M0 / G2
M10 b CRC metastasis liver 25 × 15 pT3N2M0 / G3
M11 b CRC metastasis liver 10 × 8 pT3pN1M0 / G2
M12 b CRC metastasis liver 15 × 8 pT3pN1M0 / G2
Abbreviations: CRC colorectal cancer, R rectum, S sigmoid, T transverse colon, A ascending colon
a Cancer TNM and grade classification in Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th ed. New York, NY: Wiley-Liss, 2002.
b Patients who received chemotherapy 1–20 months before resection of the liver metastasis. All other donors were chemo-naïve when sampled tumors
were resected
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Raw methylome data are deposited in ArrayExpress
(accession number: E-MTAB-8232).
Detection of differential methylation
MBD-sequencing reads were aligned to the GRCh37/
hg19 human reference genome using bwa (version
0.7.12-r1039) and the BWA-MEM algorithm [23] and
de-duplicated with Picard (Picard Toolkit, version 2.13.2;
2018. Broad Institute, GitHub Repository: http://broad-
institute.github.io/picard/).
The R-package csaw (version 1.14.1) [24] was used to
identify regions that were differentially methylated in
neoplastic tissues (primary and/or metastatic) vs. normal
mucosa or in metastatic vs. primary cancers. The num-
ber of reads per sample was counted in consecutive
overlapping windows (length: 200-bp, overlap: 190 bp).
Windows with minimum count sums of 30 across sam-
ples were kept. Additional filtering was used to exclude
windows with average log counts per million that were
below − 1. Reads aligned to the X or Y chromosome
were excluded from analysis. The csaw package uses
methods from edgeR (version 3.22.3) to identify differen-
tial binding [25] (i.e., NB GLM model to fit read counts).
Each filtered window was tested for differential methyla-
tion (i.e., differential binding of the methyl-binding pro-
tein) associated with disease status (CRC, primary or
metastatic, vs. normal mucosa) or disease stage (primary
vs. metastatic CRC). After testing, windows separated by
no more than 50 bp were merged to form regions, and
P-values were calculated for each region using the Simes
method, as described in the package. Differentially meth-
ylated regions (DMRs) were classified as hypermethy-
lated or hypomethylated based on the direction of the
methylation change in the majority of windows included
in the region.
Regions were annotated using the annotatr R-package
[26], which overlays regions of interest with predefined
annotations from external sources. Annotations were
grouped to create three “intragenic” categories: 1) regu-
latory: genomic regions 5 kb upstream from the TSS,
and 5’UTRs; 2) gene body: exons and introns (from the
end of the 5’UTR to the beginning of the 3’UTR); and 3)
the 3’UTRs. Everything outside these regions was con-
sidered “extragenic” (Fig. 1A). Regions were also classi-
fied based on their CpG density: CpG islands and the
CpG shores and shelves flanking them were grouped to-
gether and referred to as an sSISs (shelf–shore-island-
shore-shelf) region, and everything outside these regions
was classified as extra-sSISs (Fig. 1D). These regions
were overlaid onto all windows tested for differential
methylation.
Visualization was performed using the ggplot2 (version
3.0.0) [27] and UpSet (version 1.3.3) [28] R-packages.
Analyses were performed with R versions 3.6.0.
Estimated CpG density
Each CpG site (CpGs) (Team TBD 2014; BSgenome.-
Hsapiens.UCSC.hg19; R package version 1.4.0.) was
centered within a 200-bp window, and the ratio of the ob-
served to expected numbers of CpGs (O:E CpG ratio) [29]
was calculated for each window, as a measure of its CpG
density (low - O:E CpG ratios < 0.3; intermediate > = 0.3
but < 0.6; high > = 0.6 – high density).
Comparison of MBDE- and targeted bisulfite-sequencing
in colorectal cancer
In a previous study [13], we used targeted bisulfite sequen-
cing (SeqCapEpi CpGiant protocol, Roche, Basel,
Switzerland) to assess DNA methylation in three CRCs (all
microsatellite-stable and CpG island methylator
phenotype-negative) and matched samples of normal mu-
cosa (ArrayExpress accession number: E-MTAB-6949). The
results of those experiments were compared with those ob-
tained in the present study with MBD-capture sequencing,
to identify potential strengths and weaknesses of the two
enrichment methods for CRC methylome characterization.
For this analysis, we considered CpGs covered by the tar-
geted enrichment (TE) procedure, those covered by MBD
enrichment (MBDE), and those covered by both en-
richment methods. Because nearby CpGs are fre-
quently co-methylated [30, 31], the log-fold change
(logFC) and P-value for each CpG site in a given
MBD-captured region were assumed to be identical to
those calculated for the region as a whole. For CpGs
covered by the TE procedure, differences in methylation
proportions and P-values were calculated with the BiSeq
R package (Hebestreit K, Klein H, 2018. BiSeq: Processing
and analyzing bisulfite sequencing data. R package version
1.22.0), by modeling the methylation level within a beta
regression and estimating the group effect, in this case pri-
mary CRC vs. normal tissue.
CpGs covered by both methods were classified according
to the CpG density of the region in which they were located
(as specified above) and the direction of the differential
methylation identified at the site in primary CRCs (vs. nor-
mal mucosa): hypermethylated (TE: difference in methyla-
tion proportions > 0; MBDE: logFC > 0 and P-value < 0.05);
hypomethylated (TE: methylation proportion difference < 0;
MBDE: logFC < 0 and P-value < 0.05); isomethylated (TE:
methylation proportion difference = 0; MBDE: logFC = 0
and P-value = > 0.05). The strength of the linear association
between the two methods was calculated with the Pearson
correlation coefficient.
DMRs identified from TE data with the BiSeq R pack-
age were overlaid with DMRs detected from MBDE
reads, and regions were classified as overlapping if they
shared a sequence of at least 1 bp.
Code implemented in the analysis is available at https://
github.com/sorjuela/livermetastasis_MBDseq_paper.
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Fig. 1 (See legend on next page.)
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Fig. 2 Genomic regions in primary CRCs or CRC liver metastases displaying differential methylation relative to that in normal colon mucosa (NM).
a and b. Differentially methylated regions (DMRs) characterized by hypermethylation and hypomethylation (vs. NM) present in primary CRCs,
metastatic CRCs, or both. c, d, e, and f. Distributions of hypermethylated and hypomethylated DMRs in the extragenic vs. intragenic genomes;
among the intragenic genome components; between the sSISs and extra-sSISs genomic segments, and among the sSISs components,
respectively. (See Figure 1 for topography of genomic segments.)
(See figure on previous page.)
Fig. 1 Genomic distribution and functional classification of MBD-captured regions within the genome. a. Schematic showing components of an
"intragenic" genomic region. Areas outside such regions were classified as "extragenic". b. MBD-captured regions (total: 322,551) classified as
extragenic vs. intragenic. c. Distribution of the 206,258 intragenic MBD-captured regions by subregions: gene regulatory (including 5'UTRs and
regions 5 kb upstream from the TSS); gene body (including exonic and intronic sequences between the end of the 5'UTR and the beginning of
the 3'UTR); and the 3'UTRs. d. Schematic showing components of an “sSISs” region (i.e., a CpG island and flanking CpG shores and shelves). Areas
outside such regions were defined "extra-sSISs". Schematics in this panel and in panel A were adapted from diagrams contained in the R-package
annotatr vignette. e. MBD-captured regions classified as sSISs vs. extra-sSISs. f. Distribution of the 53,521 sSISs MBD-captured regions by
subregions (CpG islands, shores, and shelves). N.B. After exclusion of the X and Y chromosomes, the human genome contains 26,361 canonical
CpG islands, 15,423 of which were covered by MBDE. (See Discussion).
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Results
DNA extracted from the 21 laser-microdissected, colorectal
tissue samples was subjected to MBD-capture sequencing
(Table 1 and Supplementary Fig. 1 in Additional Files).
Fig. 1 shows the genomic locations of the 322,551 methyl-
ated regions isolated with this technology. Most (64%) were
located in the “intragenic” genome, which contains coding
genes, their regulatory segments, and 3’UTRs (Fig. 1a and
b), and 73% of these intragenic regions were situated within
a gene body (Fig. 1c). As for CpG statuses (Fig. 1d), 17% of
all the captured regions were located in sSISs sequences
(Fig. 1e), predominantly (73%) in CpG shores or shelves ra-
ther than islands (Fig. 1e).
Few of the 322,551 MBD-captured regions displayed
significant differential methylation (defined by an ad-
justed P-value cutoff of 0.05) in the cancer tissues (n =
2155 in the primary CRCs; n = 3223 in the liver metasta-
ses) in comparison with normal mucosal samples (Fig. 2,
Supplementary Table 1 in Additional file 5), and no
DMRs were identified when primary and metastatic can-
cers were compared. Five of the 12 liver metastases came
from patients who had received chemotherapy 1–20
months before liver resection (Table 1). No significant
differences were found between their methylomes and
those of the seven metastases from chemo-naïve pa-
tients. For this reason, all 12 metastatic lesions were
considered as a single group in the statistical analysis.
The vast majority of DMRs identified in tumor tissues
(94% of those in the primaries, 70% in metastases) were
hypermethylated relative to the normal mucosa. In con-
trast, hypomethylated DMRs were generally less com-
mon, and almost all of them were found in liver
metastases rather than in the primary tumors (Fig. 2a
and b). Hypomethylated DMRs were thus a distinctive
feature of the metastatic lesions (Fig. 2b), whereas most
hypermethylated DMRs were found in both types of
neoplastic tissue (Fig. 2a). In both primary CRCs and
metastases, hypermethylated DMRs were far more abun-
dant in intragenic than extragenic regions (Fig. 2c), in
regulatory segments than in gene bodies or 3’UTRs
(Fig. 2d), in sSISs than in extra-sSISs segments (Fig. 2e),
and in CpG islands than in CpG shores/shelves (Fig. 2f).
In contrast, hypomethylated DMRs were equally repre-
sented in the extragenic and intragenic genomes (Fig. 2c).
Within intragenic regions, they were more frequent in
gene bodies (than in regulatory segments or 3’UTRs)
(Fig. 2d). Hypomethylation was more common in the
extra-sSISs genome (Fig. 2e), but those located within
sSISs areas displayed similar frequencies in CpG islands,
shores, and shelves (Fig. 2f). The distribution of DMR
lengths among the genomic segments discussed above is
shown in the Additional Files (Supplementary Fig. 2).
As detailed in the Methods section, we then compared
the primary CRC methylomes characterized with MBDE
with the results obtained in other primary CRCs using
TE [13]. As shown in Fig. 3a, MBDE covered a larger
portion of the genome with a higher CpG content
(249.5Mb containing ~ 7,6 million CpGs vs. ~ 79.1Mb
with ~ 2.8 million CpGs with TE), and around 1,1 mil-
lion CpGs were captured by both methods. Both
methods preferentially covered CpGs in regions where
the density of these dinucleotides was relatively high
(Fig. 3b), and 1,105,282 (96.5%) of the CpGs covered by
both methods were located in regions with an intermedi-
ate- or high-CpG density (Fig. 3c).
Cancer-associated changes in methylation levels identi-
fied with the MBDE and TE displayed a moderately strong
positive correlation (r: from 0.59 to 0.65, Fig. 3c, upper
panel). However, the methods differed substantially in
calling hyper- or hypomethylation at individual CpGs
(Fig. 3c, lower panel). Of the 1,144,600 CpGs covered by
both methods, 57,077 (5%) were concordantly identified
as hypermethylated and 30,525 (2.7%) as hypomethylated.
More frequently, however, the two methods yielded dis-
cordant results: indeed, 163,841 (14.3%) of the CpGs were
identified as significantly hypermethylated only with
MBDE, and a similar proportion (n = 167,545 [14.6%])
emerged as significantly hypomethylated only with TE.
Accordingly, hypermethylated DMRs were more fre-
quently identified in primary CRCs with MBDE than with
TE, whereas hypomethylated DMRs were almost exclu-
sively identified with TE (Fig. 3d, and examples of DMRs
in Additional Files, Supplementary Fig. 3). The lower
number of hypermethylated DMRs identified with TE was
due in part due to the lack of SeqCapEpi CpGiant probes
targeting many of the regions found to be hypermethy-
lated with MBDE (Supplementary Fig. 3B) and in part to
the different computational approaches used to analyze
the MBDE and TE data sets (Supplementary Fig. 3C). As
for the difference involving hypomethylated DMRs, it
probably reflects the fact that these regions were generally
shorter than their hypermethylated counterparts and dis-
played less markedly altered methylation levels (hypo
beta-value mean: 0.21, hyper beta-value mean: 0.31; see
also Supplementary Table 1, Supplementary Figs. 2 and 3
D-E, and Fig. 1e of our previous study [13]).
Discussion
We used a high-stringency MBD-protein-based enrich-
ment protocol to obtain methylated DNA for deep se-
quencing from CRCs (primary and liver metastases) and
normal colon mucosa. The portion of the genome se-
quenced (7.8%) included ~ 27% of the ~ 28 million CpGs
found therein (~ 7.6 × 106). Small fractions of the MBD-
isolated regions were differentially methylated in primary
(2155 regions including 279,441 CpGs) or metastatic
CRC (3223 regions containing 312,723 CpGs) samples
relative to the unmatched samples of normal colon
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Fig. 3 Performance of MBD enrichment (MBDE) and targeted enrichment (TE) in identifying differentially methylated CpGs or regions (DMRs) in primary
CRCs (vs. normal mucosa). a. Compared with TE, MBDE captured 3 times more genomic base pairs (including 33.4% of TE-captured base pairs) and almost
3 times more CpGs (including 41.3% of TE-captured sites). b. First three density plots, from left: Compared with CpGs missed by both methods (mean O:E
CpG ratios: 0.35 for MBDE, 0.39 for TE), the CpGs captured by each method were preferentially located in genomic areas with relatively high CpG densities
(mean O:E CpG ratios: 0.58 for MBDE, 0.65 with TE). Fourth density plot: CpGs captured by MBDE only, by TE only or by both methods tended to be
located in genomic areas with similar CpG densities (mean O:E CpG ratios: 0.56 for MBDE, 0.65 for TE, 0.66 for both methods). c. Methylation changes (log
fold change in MBDE, beta-values in TE) at CpGs captured by both methods in low-, medium-, and high-CpG-density areas. (See Methods for calculation of
differential methylation with each method and for calculation and classification of CpG density.) Intermethod correlation values are shown for each density
area. For most of the CpGs captured by both methods (gray bars), no methylation differences in primary CRCs (vs. normal mucosa) were identified with
either MBDE or TE. The number of hypermethylated CpGs detected by both methods (red bars) steadily increased with increasing CpG rates. In addition, in
medium- and high-CpG-rate areas of the genome, MBDE captured hypermethylated CpGs that were not found to be significantly hypermethylated with
TE (blue vs. green bars). Hypomethylated CpGs were more frequently identified by TE than MBDE (yellow vs. orange bars). d. The CpG site trends were
confirmed by analysis of DMRs. Over 400 hypermethylated DMRs were identified with both methods (in addition to the 1584 identified only by MBDE and
the 827 detected only with TE). However, the overlap of commonly identified hypermethylated DMRs is likely underestimated because of the use of
different analytical packages to identify them with MBDE or TE (see example in Supplementary Figure 3 C). Hypomethylated DMRs were in contrast
identified almost exclusively by TE (examples in Supplementary Figure 3 D and E).
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mucosa we tested. Importantly, the hypermethylation
phenotype of the liver metastases closely resembled that
of primary CRCs, in terms of both the identity and loca-
tion of the hypermethylated DMRs. We have previously
shown that this phenotype is already evident in precan-
cerous colorectal lesions (i.e., sessile serrated lesions
and, to a lesser extent, adenomatous polyps), and it be-
comes increasingly obvious in CRCs [13]. Our present
findings suggest that this progression reaches a plateau
before CRC cells seed the liver. In contrast, the spread
of CRC-associated hypomethylation continues after the
tumor cells metastasize to the liver. The extent of this
progression requires further investigation with whole-
genome analysis of the methylome (see below), but it is
tempting to speculate that late increases in hypomethy-
lation might contribute to metastasis-specific alterations
in the gene expression, genomic stability, and/or drug
susceptibility of CRCs [32–36].
Our study is the first to use genome-wide deep-
sequencing to compare the methylomes of primary CRCs
and CRC liver metastases. To our knowledge, only three
previous studies [37–39] have analyzed this issue at the
genome-wide level. In two studies, freshly collected,
patient-matched tissue pairs (nine in one case [37], three in
the other [38]) were analyzed using a methylated CpG is-
land amplification microarray approach involving
methylation-specific, restriction-enzyme digestion of de-
fined CpGs in approximately 6000 gene promoters [40, 41].
Both found that the hypermethylation phenotypes of CRC
liver metastases closely resembled those of their primary
cancer counterparts, leading the investigators to conclude
—as we have— that most of the DNA hypermethylation as-
sociated with colorectal tumorigenesis probably occurs be-
fore the disease spreads to the liver. Our in silico analysis of
previously published llumina Infinium 450 microarray data
on six patient-matched tissue pairs [39] also confirmed that
the methylomes of primary and metastatic colorectal can-
cers are similar (Additional Files, Supplementary Fig. 4).
This conclusion is also supported by findings of a recent
analysis of 70 pairs of formalin-fixed, paraffin-embedded
tissues, which revealed concordance between primary CRCs
and matched metastases taken from different organs in the
CpG island hypermethylation phenotype at five gene pro-
moters [42]. The tissues we tested were prospectively col-
lected to obtain, from fresh samples, high-quality DNA for
MBD capture, and this markedly reduced our chances of
obtaining matched samples of colorectal cancers and their
corresponding liver metastases in the timeframe of the
study. (The clinical management of patients with colorectal
cancer—before and after detection of liver metastases—is
usually a fairly long process marked by multiple surgical
and chemotherapeutic interventions, often carried out in
different hospitals.) Although this is undeniably a limitation,
the strikingly similar hypermethylation phenotypes
observed in the unmatched primary and metastatic tumors
suggests that similar or even greater concordance would
probably be evident in matched samples. Our use of laser-
capture tissue microdissection probably played a key role in
reducing the variability between primary and metastatic
epithelial tumors by eliminating normal and tumor-related
stromal cells from their respective microenvironments, an
important aspect that recently emerged in a gene-
expression study of primary and metastatic colorectal can-
cers [43].
Our findings on hypomethylation are also in agree-
ment with the previous observations of Hur et al. [35],
who found hypomethylation of long interspersed nuclear
element-1 (LINE-1) sequences in 77 formalin-fixed,
paraffin-embedded samples of primary CRCs (vs. normal
mucosa), and this alteration was even more evident in
matched samples of liver metastases. The fact that some
of the hypomethylated LINE-1 sequences were found to
be located within the intronic regions of proto-
oncogenes whose expression was increased in liver
metastases points intriguingly to possible functional con-
sequences of the late increase of hypomethylation in
cancer cells seeding in the liver [35].
The present study was conducted exclusively on
microsatellite stable/non-CIMP CRCs, which are far
more common than CRC with MSI/CIMP-H phenotype.
The decision to focus our work on the more frequently
encountered phenotype was motivated by the difficulties
we encountered in the prospective collection of samples
(see above) and the costs of the genome-wide analysis of
the DNA methylome. In addition, our previous work
[13] has shown that the DNA methylome of primary
microsatellite stable/non-CIMP CRCs differs from that
of MSI/CIMP-H primaries. Data in the literature are
lacking on the possible evolution of the MSI/CIMP-H
CRC methylome during metastasis. Genome-wide ana-
lysis of the methylome should therefore be extended to
this molecular type of CRCs to determine whether hyper
−/hypomethylation changes between primary and meta-
static tumors are CRC-type specific.
We found no evidence that chemotherapy significantly
alters the methylomes of CRC liver metastases. This is
an important issue in view of the emergence of drug-
resistant clones that might exhibit clinically-relevant epi-
genomic changes [44, 45], and our finding obviously re-
quires further and more in-depth investigation. The
timing of chemotherapy relative to primary and meta-
static tumor resections varied widely in our study, as did
the drugs administered. All, however, were cytotoxic
agents, and it is important to extend the investigation to
include the possible effects of more recently introduced
targeted approaches, such as anti-EGFR antibodies.
Bisulfite sequencing is still considered the gold stand-
ard technique for analyzing DNA methylomes. However,
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bisulfite conversion of unmethylated cytosines causes
substantial DNA damage [46, 47], which can be a major
concern when the amount of input DNA extracted from
clinical samples is limited (e.g., the laser-microdissected
sections of frozen tissues used in our study). Using
MBDE, we obtained high-quality methylome data with
only 100 ng of input DNA per sample, but reliable re-
sults with this enrichment method can reportedly be ob-
tained with volumes as small as 15 ng [48]. Furthermore,
owing to cost considerations and computational con-
straints, bisulfite sequencing analysis is usually limited to
a genome-wide selection of regions, such as that ob-
tained with the targeted enrichment step we used for
our bisulfite-sequencing analysis of the methylomes of
normal, precancerous, and cancerous colorectal tissues
[13]. Metastatic CRCs were not included in that study,
but comparison of the data it generated on primary can-
cers and normal mucosa with those obtained here pro-
vided insights into the pros and cons of the two pre-
sequencing enrichment protocols (Fig. 3).
As expected, MBDE covered a larger portion of the gen-
ome and more CpG dinucleotides than TE (Fig. 3a). The
probes used for TE, which were designed a priori, target
specific genomic loci consisting mainly of CpG islands in
regulatory regions [13]. In contrast, MBDE relies on the
binding of the MBD polypeptide to any of the numerous
methylated regions in the genome—extragenic as well as
intragenic, and CpG shores and shelves as well as the
islands they flank (Fig. 1b-c). Therefore, MBDE allowed us
to recover more genomic information than TE.
Our analysis also confirmed that both MBDE and TE
preferentially cover CpG-dense regions (Fig. 3b), but the
mean O:E CpG ratio of those covered by TE was slightly
higher than that of MBDE-covered regions (difference be-
tween means = 0.075). This small increase is consistent
with the fact that TE detected 25,291 (96%) of the 26,361
“canonical” CpG islands located in non-sex chromosomes,
as opposed to only 15,423 (59%) detected with MBDE.
Most CpG islands are unmethylated in human tissues [49,
50] and will therefore be missed by the MBD polypeptide,
which binds to methylated regions [22]. In contrast, how-
ever, the shores and shelves flanking canonical CpG
islands are not missed by MBDE since they are usually
methylated. Indeed, by considering a broader window that
includes shelves and shores, as well as the island they flank
(i.e., sSISs), MBDE actually covered 93.5% of these regions
(24,644, Fig. 1f).
As for the CpG sites covered by both enrichment
technologies, previous comparisons have shown high
concordance in the methylation levels identified, in
non-colorectal cells or tissues, by MBDE and
bisulfite-sequencing approaches (reduced representa-
tion bisulfite sequencing [51] and whole genome bi-
sulfite sequencing [52, 53]). Unlike these studies, our
work included both diseased tissues (i.e., cancers) and
normal colorectal tissues, with the latter as a refer-
ence. We could thus focus on methylation level alter-
ations in primary CRCs, as compared with basal
levels observed in normal colorectal mucosa, and we
also assessed the performance of MBDE vs. TE in re-
gions differing in CpG-density (Fig. 3c). On the
whole, the methylation changes identified with the
two methods were concordant, with correlation values
ranging from 0.59 to 0.65 (Fig. 3d). Significant
changes in methylation were observed in high-, inter-
mediate, and low-CpG-density regions. Interestingly,
however, MBDE identified hypermethylation in high-
density regions that was not detected by TE, and TE
consistently detected more hypomethylation, regard-
less of the regions’ CpG density (Fig. 3c-d). The latter
difference was likely due to the limited magnitude of
the changes involving hypomethylation and their ten-
dency to occur in relatively short stretches of DNA.
Both factors reduce the odds that these alterations
will be detected by MBDE, which cannot quantify
methylation levels at single CpGs [51, 52].
Despite the evidence for concordance between MBDE
and TE, the differences (e.g., those related to cost, cover-
age achieved, and resolution) should also be considered
when choosing between the two types of enrichment pro-
tocols (see [51, 54] for formal comparisons). In general,
for the study of regional methylation, single-CpG reso-
lution might not be necessary, and a lower-cost method of
enrichment like MBDE can be used. Targeted enrichment,
however, is more suitable when there is a need for CpG
resolution of methylation levels (e.g., identification of
methylation at transcription-factor binding sites).
Conclusions
While tumor-associated hypermethylation at specific
genomic regions—promoters in particular—appears to
be a progressive phenomenon that plateaus before CRC
cells disseminate to the liver, the progression of CRC-
associated hypomethylation seems to continue in meta-
static lesions, with low-magnitude changes that are
nonetheless evident throughout the genome. At this
stage, the clinical implications of our findings are un-
known. One can reasonably speculate, however, that the
relatively fixed nature of the CRC hypermethylome
could render liver metastases less “flexible” and conse-
quently more vulnerable to certain medical treatments,
whereas the ongoing extension of hypomethylation after
liver seeding might lead to the emergence of adaptive
changes favoring drug resistance. Further study of this
issue, using methods capable of characterizing whole-
genome DNA methylation and gene expression, is there-
fore important since it might well reveal new prospects
for the treatment of patients with late-stage CRC.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12885-020-06777-6.
Additional file 1: Supplementary Fig. 1. MDS (multidimensional
scaling) plot of DNA methylation levels in the 21 samples included in the
study. While normal mucosa samples (blue circles) were clustered
together and separated from tumors, there is no obvious separation
between CRCs (red circles) and liver metastases (green circles).
Additional file 2: Supplementary Fig. 2. DMR length distribution.
Length in base pairs of hypermethylated and hypomethylated DMRs in:
A. the extragenic vs. intragenic genomes; B. among the intragenic
genome components; C. the sSISs and extra-sSISs genomic segments;
and D. among the sSISs components. NM: normal mucosa, CRC: primary
cancer, Met: metastasis.
Additional file 3: Supplementary Fig. 3. Integrative Genomics Viewer
snapshots showing examples of significantly hyper- or hypomethylated
DMRs detected with MBDE, TE, or both enrichment methods.
Abbreviations: DMR: differentially methylated region; MBDE: MBD
enrichment; TE: targeted enrichment; NM: normal mucosa; CRC: colorectal
cancer. Tracks corresponding to NM samples, primary CRCs, and CRC liver
metastases are shown in blue, red, and green, respectively. For MBDE,
track-landscape heights indicate read depth; for TE, track-bar heights indi-
cate the methylation level (%) at a given CpG site. A: Large, hypermethy-
lated DMR overlapping the CpG island in the EYA4 promoter, detected by
both methods. B: Four consecutive, hypermethylated DMRs detected by
MBDE. The fourth one was also detected by TE, with a probe directed
specifically at CpG island no. 37 at this genomic locus. C: This DMR was
found to be significantly hypermethylated only with MBDE. At the ad-
justed P-value cutoff used in the analysis of TE data, the differential
methylation in this region was not significant, although methylation
levels at many CpG sites (indicated by bar heights) are clearly higher in
primary CRCs than in NM samples. D and E: Examples of hypomethylated
DMRs detected only with TE: like most of the hypomethylated DMRs we
found, these two are shorter than the hypermethylated DMRs. In general,
the hypomethylated DMRs were also characterized by relatively small dif-
ferences with respect to the methylation levels in NM. (See Results and
Discussion.)
Additional file 4: Supplementary Fig. 4. In-silico analysis of Gene Ex-
pression Omnibus DataSet GSE53051 (submitted by Timp et al., reference
[39]). For each sample, the normalized average beta values per probe
were downloaded. A. MDS (multidimensional scaling) plot of the beta
values for 6 patients with paired normal mucosa (NM), primary cancer
(CRC) and liver metastasis (Met). The limma package (reference [25]) was
used to identify the 1000 probes displaying the highest variability and to
plot the MDS. Consistent with the findings of our own study (Supple-
mentary Fig. 1), normal mucosa samples from the DataSet clustered to-
gether and were appreciably separated from tumors, whereas there was
no obvious separation between CRCs and liver metastases. B. Scatter
plots of the mean beta values per tissue (Met vs NM, CRC vs NM, CRC vs
Met) for all the probes (Genome, top 3 plots), and for probes located in
CpG Islands (Islands, bottom 3 plots). CRCs and Mets had similar methy-
lomes, both with Genome and Island probes (top and bottom panels on
the right, respectively), while skewed profiles towards hypomethylation
(Genome probes) or hypermethylation (Islands probes) in tumors (vs NM)
were detected (the four panels on the left and in the middle). C. The
similarity of the CRC and Met methylation patterns is also reflected by
the mean beta values per sample across all probes (Genome, top) and
the probes in CpG Islands (Islands, bottom).
Additional file 5: Supplementary Table 1.
Abbreviations
CpGs: CpG sites; CIMP: CpG island methylator phenotype; CRC: Colorectal
cancer; DMRs: Differentially methylated regions; FDR: False discovery rate;
logFC: Log-fold change; MBD: methylCpG binding domain; MBDE: MBD
protein-mediated enrichment; MSI: Microsatellite instability; O:E CpG
ratio: Ratio of the observed to expected numbers of CpGs; sSISs: Shelf-shore-
island-shore-shelf; TE: Targeted enrichment
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